Blair William & Co. IL Has $199.46 Million Holdings in Zoetis Inc. $ZTS

Blair William & Co. IL reduced its stake in Zoetis Inc. (NYSE:ZTS) by 16.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,363,155 shares of the company’s stock after selling 268,716 shares during the quarter. Blair William & Co. IL owned approximately 0.31% of Zoetis worth $199,457,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ZTS. First Trust Advisors LP boosted its stake in Zoetis by 342.1% during the third quarter. First Trust Advisors LP now owns 1,485,459 shares of the company’s stock worth $217,352,000 after buying an additional 1,149,467 shares in the last quarter. HUB Investment Partners LLC raised its stake in shares of Zoetis by 24.3% in the 3rd quarter. HUB Investment Partners LLC now owns 2,786 shares of the company’s stock valued at $408,000 after buying an additional 545 shares in the last quarter. Intellectus Partners LLC lifted its holdings in shares of Zoetis by 30.4% during the 3rd quarter. Intellectus Partners LLC now owns 8,931 shares of the company’s stock worth $1,307,000 after acquiring an additional 2,082 shares during the period. Heron Bay Capital Management boosted its position in shares of Zoetis by 36.2% during the 3rd quarter. Heron Bay Capital Management now owns 43,224 shares of the company’s stock valued at $6,325,000 after acquiring an additional 11,490 shares in the last quarter. Finally, Aptus Capital Advisors LLC raised its position in Zoetis by 17.2% in the third quarter. Aptus Capital Advisors LLC now owns 20,793 shares of the company’s stock worth $3,042,000 after purchasing an additional 3,045 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.6%

Shares of NYSE:ZTS opened at $121.54 on Friday. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.00. The company’s 50-day moving average price is $126.06 and its two-hundred day moving average price is $133.20. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a market cap of $51.31 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.87 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the previous year, the firm posted $1.40 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research report on Monday, December 15th. Barclays initiated coverage on shares of Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price on the stock. Stifel Nicolaus reduced their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday. Finally, Morgan Stanley set a $160.00 price objective on shares of Zoetis in a report on Thursday, December 18th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.